Helen Diller Family Comprehensive Cancer Center

New presurgery combination therapy for triple-negative breast cancer

Tuesday, December 17, 2013

The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete testing in the trial. Adding the chemotherapy carboplatin and the molecularly targeted drug veliparib to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer.

[Read More]